Jason Aryeh
Jason Aryeh's purchase track record
Jason Aryeh has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/15/2026 | OBIO | $37K | +18.6% | pending | — |
| 9/19/2025 | OBIO | $2K | +78.3% | +90.2% | -2.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Lifecore Biomedical to be acquired by Webster Equity Partners. Lifecore Biomedical has announced it will be acquired by Webster Equity Partners in a deal valued at up to $663.7 million. Shareholders may receive up to $9.67 per common equivalent, combining cash and contingent value rights based on performance milestones. This transaction is significant as it represents a full exit for the company, with the potential payout exceeding the current average analyst target of $6.75.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
OBIO Shares Rise 5.2% Amid Positive Momentum. Orchestra BioMed Holdings (OBIO) shares recently increased by 5.2%, a move that some observers see as a sign of strengthening momentum. The stock currently trades within its 52-week range of $2.20 to $6.48. Analysts maintain an average price target of $12.14, suggesting a significant gap between the current market price and professional estimates.
Transaction History
| LGND | ▼ Sell | Open Market | 4,500 | $1.1M | 6/11/2026 | View on chart |
| LGND | ▼ Sell | Open Market | 500 | $125K | 6/10/2026 | View on chart |
| LGND | ▲ Buy | Grant | 836 | $0 | 6/5/2026 | View on chart |
| LFCR | ▲ Buy | Grant | 25,907 | — | 6/4/2026 | View on chart |
| OBIO | ▲ Buy | Open Market | 665 | $2K | 5/18/2026 | View on chart |
| OBIO | ▲ Buy | Open Market | 8,971 | $35K | 5/15/2026 | View on chart |
| LGND | ▲ Buy | Option Exercise | 2,034 | $141K | 12/8/2025 | View on chart |
| LGND | ▼ Sell | Open Market | 4,418 | $753K | 9/23/2025 | View on chart |
| LGND | ▼ Sell | Open Market | 4,628 | $791K | 9/23/2025 | View on chart |
| LGND | ▼ Sell | Open Market | 954 | $164K | 9/23/2025 | View on chart |
| OBIO | ▲ Buy | Open Market | 1,000 | $2K | 9/19/2025 | View on chart |
| OBIO | ▲ Buy | Grant | 15,000 | $0 | 8/7/2025 | View on chart |
| LFCR | ▲ Buy | Grant | 19,506 | — | 7/15/2025 | View on chart |
| OBIO | ▲ Buy | Grant | 12,422 | $0 | 6/24/2025 | View on chart |
| LGND | ▲ Buy | Grant | 1,209 | $0 | 6/6/2025 | View on chart |
| OBIO | ▲ Buy | Option Exercise | 11,700 | $50K | 12/27/2024 | View on chart |
| LFCR | ▲ Buy | Grant | 24,554 | — | 8/19/2024 | View on chart |
| OBIO | ▲ Buy | Grant | 5,376 | $0 | 6/20/2024 | View on chart |
| LGND | ▲ Buy | Grant | 1,252 | $0 | 6/14/2024 | View on chart |
| LGND | ▲ Buy | Option Exercise | 2,406 | $126K | 4/30/2024 | View on chart |
| LGND | ▲ Buy | Option Exercise | 2,893 | $114K | 3/5/2024 | View on chart |
| LGND | ▲ Buy | Grant | 1,142 | $0 | 6/9/2023 | View on chart |
| OBIO | ▲ Buy | Option Exercise | 11,246 | — | 4/12/2023 | View on chart |
| OBIO | ▲ Buy | Grant | 51,738 | — | 1/26/2023 | View on chart |
| LGND | ▲ Buy | Grant | 1,004 | $0 | 6/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Ligand Pharmaceuticals Releases Q2 2026 Earnings Call Transcript
Ligand Pharmaceuticals has published the full transcript of its second-quarter 2026 earnings call, providing investors with detailed management commentary on recent performance. While the stock currently trades near a key support level, the release of this transcript offers a deeper look into the company's operational updates and strategic outlook beyond the headline financial figures.
Ligand Pharmaceuticals Releases Q2 2026 Earnings Call Transcript. Ligand Pharmaceuticals has published the full transcript of its second-quarter 2026 earnings call, providing investors with detailed management commentary on recent performance. While the stock currently trades near a key support level, the release of this transcript offers a deeper look into the company's operational updates and strategic outlook beyond the headline financial figures.